VITAMIN D DEFICIENCY AND DEPRESSIVE DISORDERS: REVIEW STUDY OF PROBABLE RELATIONSHIP

  • Wissam Zam Department of Analytical and Food Chemistry, Faculty of Pharmacy, Al-Andalus University for Medical Sciences, Al-Quadmous, Tartous, Syrian Arab Republic

Abstract

Vitamin D deficiency is evident in many parts of the world, even in the sunnier regions, for a variety of reasons. Recently, vitamin D has been reported in many scientific researchers as an important factor that may have significant health benefits in the prevention and the treatment of many chronic illnesses such as depression. According to the Global Burden of Disease Study, depression is one of the world's leading causes of disability and affects 350 million people in all communities across the world. Depressive disorders often start at an early age; they reduce people's functioning, and they are the leading cause of disability worldwide in terms of total years lost due to disability. The demand for curbing and preventing depression is on the rise globally. The present review will highlight the relation between vitamin D deficiency and the risk of depression among the different population. It will also discuss the epidemiology of vitamin D supplementation and depression from a variety of sources both suggesting and disproving their relation.

Keywords: Curbing, Deficiency, Depression, Preventing, Supplementation, Vitamin D

Downloads

Download data is not yet available.

References

1. Brown AJ, Dusso A, Slatopolsky E. Vitamin D. Am J Physiol 1999;277:157–75.
2. Holick MF. Photosynthesis of vitamin D in the skin: effect of environmental and lifestyle variables. Fed Proc 1987;46:1876–82.
3. Belitz HD, Grosch W, Schieberle P. Food Chemistry. 4th ed. Springer-Verlag Berlin: Heidelberg; 2009.
4. Holick MF. Vitamin D: a millennium perspective. J Cell Biochem 2003;88:296–307.
5. Norman AW. From vitamin D to hormone D: fundamentals of the vitamin D endocrine system essential for good health. Am J Clin Nutr 2008;88:1S–499S.
6. Holick MF, Tian XQ, Allen M. Evolutionary importance for the membrane enhancement of the production of vitamin D3 in the skin of poikilothermic animals. Proc Natl Acad Sci 1995;92:3124–6.
7. Holick MF, Garabedian M. Vitamin D: photobiology, metabolism, mechanism of action, and clinical applications. 6th ed. Favus MJ. editor. Washington DC: American Society for Bone and Mineral Research; 2006.
8. Fraser DR. Regulation of the metabolism of vitamin D. Physiol Rev 1980;60:551–613.
9. Dusso AS, Tokumoto M. Defective renal maintenance of the vitamin D endocrine system impairs vitamin D renoprotection: a downward spiral in kidney disease. Kidney Int 2011;79:715-29.
10. Holick MF. Vitamin D status: measurement, interpretation, and clinical application. Ann Epidemiol 2009;19:73-8.
11. Holick MF. Resurrection of vitamin D deficiency and rickets. J Clin Invest 2006;116:2062-72.
12. Otten JJ, Hellwig JP, Meyers LD. Dietary reference intakes: The essential guide to nutrient requirements. Washington, DC: National Academies Press; 2006.
13. Wagner CL, Greer FR. The section on breastfeeding and committee on nutrition. prevention of rickets and vitamin d deficiency in infants, children, and adolescents. Pediatrics 2008;122:1142–52.
14. Thomas KK, Lloyd-Jones DM, Thadhani RI. Hypovitaminosis D in medical inpatients. N Engl J Med 1998;338:777-83.
15. Heaney RP, Dowell MS, Hale CA, Bendich A. Calcium absorption varies within the reference range for serum 25-hydroxyvitamin D. J Am Coll Nutr 2003;22:142-6.
16. Dawson-Hughes B, Heaney RP, Holick MF, Lips P, Meunier PJ, Vieth R. Estimates of optimal vitamin D status. Osteoporosis Int 2005;16:713-6.
17. Coburn JW, Brautbar N. Disease states in man related to vitamin D. Norman AW. editor. New York: Marcel Dekker; 1980.
18. Haddad JG, Chyu KJ. Competitive protein-binding radio-assay for 25-hydroxycholecalciferol. J Clin Endocrinol Metab 1971;33:992.
19. Christiansen C, Christiansen MS, Melsen F, Rodbro P, DeLuca HF. Mineral metabolism in chronic renal failure with special reference to serum concentrations of 1,25(OH)2D and 24,25(OH)2D. Clin Nephrol 1981;15:18.
20. Brickman AS, Coburn JW, Norman AW, Massry SG. Short-term effects of 1,25-dihydroxycholecalciferol on disordered calcium metabolism of renal failure. Am J Med 1974;57:28.
21. Lund B, Sorensen OH, Lund B, Bishop JE, Norman AW. Vitamin D metabolism in hypoparathyroidism. J Clin Endocrinol Metab 1980;51:606.
22. Lindeman RD, Tobin J, Shock NW. Longitudinal studies on the rate of decline in renal function with age. J Am Geriatr Soc 1985;33:278.
23. Ginde AA, Liu MC, Camargo CA. Demographic differences and trends of vitamin D insufficiency in the US population, 1988–2004. Arch Intern Med 2009;169:626–32.
24. Harris S. Vitamin D and african americans. Acad J Nutr 2006;136:1126–9.
25. Wortsman J, Matsuoka LY, Chen TC, Lu Z, Holick MF. Decreased bioavailability of vitamin D in obesity. Am J Clin Nutr 2000;72:690–3.
26. McGill AT, Stewart JM, Lithander FE, Strik CM, Poppitt SD. Relationships of low serum vitamin D3 with anthropometry and markers of the metabolic syndrome and diabetes in overweight and obesity. Nutr J 2008;7:4.
27. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th Edition. American Psychiatric Association, Washington DC. text revision; 2000.
28. Spijker J, De Graaf R, Bijl RV. Duration of major depressive episodes in the general population: results from the Netherlands mental health survey and incidence study (NEMESIS). Br J Psychiatry 2002;181:208-13.
29. Washington DC. Evidence report on the treatment of depression: Newer Pharmacotherapies. San Antonio Evidence-Based Practice Centre. Transplant Proc; 1999. p. 99-E014.
30. Kupfer DJ. Long-term treatment of depression. J Clin Psychiatry 1991;52:28-34.
31. World Health Organization. Depression; 2008.
32. Agency for Health Care Policy and Research. Depression Guideline Panel. Depression in Primary Care: Vol. 1. Detection and Diagnosis. Clinical Practice Guideline, Number 5. Rockville, Maryland: U. S Department of Health and Human Services; 1993. p. 93-0550.
33. Judd LL. The clinical course of unipolar major depressive disorders. Arch Gen Psychiatry 1997;4:989-91.
34. World Health Organization. The Global Burden of Disease; 2008. Available from: http://www.who.int/ health info/ global_burden_disease/GBD_report_2004update_full.pdf. [Last accessed 16 Jun 2012].
35. Rahman A, Patel V, Maselko J, Kirkwood B. The neglected ‘m’ in MCH programs–why mental health of mothers is important for child nutrition. Trop Med Int Health 2008;13:579-83.
36. Flint J, Muafo MR. The endophenotype concept in psychiatric genetics. Psychol Med 2007;37:163–80.
37. Caspi A, Sugden K, Moffitt TE, Taylor A, Craig IW, Harington H, et al. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 2003;301:386–9.
38. Patten SB, Wang JL, Williams JVA, Currie SR, Beck CA, Maxwell CJ, et al. Descriptive epidemiology of major depression in Canada. Can J Psychiatry 2005;51:84–90.
39. Offord DR, Boyle MH, Campbell D, Goering P, Lin E, Wong M, et al. One-year prevalence of psychiatric disorder in Ontarians 15 to 64 y of age. Can J Psychiatry 1996;41:559–63.
40. Kendler KS, Karkowski LM, Prescott CA. Causal relationship between stressful life events and the onset of major depression. Am J Psychiatry 1999;156:837–41.
41. Willis-Owen SA, Turri MG, Munafu MR, Surtees PG, Wainwright NWJ, Brixey RD. The serotonin transporter length polymorphism, neuroticism, and depression: a comprehensive assessment of association. Biol Psychiatry 2005;58:451–6.
42. Whooley MA, de Jonge P, Vittinghoff E, Otte C, Moos R, Carney RM, et al. Depressive symptoms, health behaviors, and risk of cardiovascular events in patients with coronary heart disease. JAMA 2008;300:2379–88.
43. Hackett ML, Anderson CS, House A, Xia J. Interventions for treating depression after stroke. Cochrane Database of Systematic Reviews 2008;8: CD003437. doi: 10.1002/ 14651858.CD003437.pub3. [Article in Press]
44. Starkstein SE, Mizrahi R, Power BD. Antidepressant therapy in post-stroke depression. Expert Opin Pharmacother 2008;9:1291.
45. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome. an American heart association/national heart, lung, and blood institute scientific statement. executive summary. Circulation 2005;112:2735–52.
46. Jensen MD, Ryan DH, Apovian CM, Ard JD, Comuzzie AG, Donato KA. AHA/ACC/TOS guideline for the management of overweight and obesity in adults: A report of the American college of Cardiology/American heart association task force on practice guidelines and the obesity society. Obesity 21; 2013.
47. Barkley R. Attention-deficit hyperactivity disorder: A Handbook for Diagnosis and Treatment. 3rd ed. New York: Guilford Press; 2006.
48. American Society of Addiction Medicine. Public policy statement: Definition of addiction; 2011. Available from: http://www.asam.org/docs/publicypolicy statements/1definition_of_addiction_long_4-11.pdf. [Last accessed on 15 Aug 2011].
49. Bent S. Herbal medicine in the United States: review and efficacy, safety, and regulation. J Gen Intern Med 2008;23:854–9.
50. Kennedy SH, Lam RW. Clinical guidelines for the treatment of depressive disorders. Can J Psychiatry 2001;46:1S–92S.
51. Gloth FM, Alam W, Hollis B. Vitamin D vs broad spectrum phototherapy in the treatment of seasonal affective disorder. J Nutr Health Aging 1999;3:5-7.
52. Lam RW, Levitt AJ, Levitan RD, Enns MW, Morehouse R, Michalak EE, et al. The Can-SAD study: a randomized controlled trial of the effectiveness of light therapy and fluoxetine in patients with winter seasonal affective disorder. Am J Psychiatry 2006;163:805–12.
53. Even C, Schroder CM, Friedman S, Rouillon F. Efficacy of light therapy in nonseasonal depression: a systematic review. J Affective Disord 2008;108:11–23.
54. Leppamaki SJ, Partonen T, Hurme J, Haukka J, Lonnqvist J. Randomized trial of the efficacy of bright-light exposure and aerobic exercise on depressive symptoms and serum lipids. J Clin Psychiatry 2002;63:316-21.
55. Partonen T, Vakkuri O, Lamberg-Allardt C, Lonnqvist J. Effects of bright light on sleepiness, melatonin, and 25-hydroxyvitamin D3 in winter seasonal affective disorder. Biol Psychiatry 1996;39:865–72.
56. Wilkins CH, Sheline YI, Roe CM, Birge SJ, Morris JC. Vitamin D deficiency is associated with low mood and worse cognitive performance in older adults. Am J Geriatric Psychiatry 2006;14:1032–40.
57. Song BM, Kim HC, Rhee Y, Youm Y, Kim CO. Association between serum 25-hydroxyvitamin D concentrations and depressive symptoms in an older Korean population: a cross-sectional study. J Affective Disord 2015;189:357-64.
58. Jorde R, Waterloo K, Saleh F, Haug E, Svartberg J. Neuropsychological function in relation to serum parathyroid hormone and serum 25-hydroxvitamin D levels: the tromso study. J Neurol 2006;253:464.
59. Armstrong DJ, Meenagh GK, Bickle I, Lee ASH, Curran ES, Finch MB. Vitamin D deficiency is associated with anxiety and depression in fibromyalgia. Clin Rheumatol 2007;26:551–4.
60. Moran LJ, Teede HJ, Vincent AJ. Vitamin D is independently associated with depression in overweight women with and without PCOS. Gynecol Endocrinol 2014;4:1-4.
61. Ozkayar N, Altun B, Ulusoy S, Yildirim T, Halil M, Yilmaz R, et al. Relationship between vitamin D levels and depressive symptoms in renal transplant recipients. Int J Psychiatry Med 2014;47:141-51.
62. Huang JY, Arnold D, Qiu CF, Miller RS, Williams MA, Enquobahrie DA. Association of serum vitamin D with symptoms of depression and anxiety in early pregnancy. Int J Women's Health 2014;23:588-95.
63. Gur EB, Gokduman A, Turan GA, Tatar S, Hepyilmaz I, Zengin EB, et al. Mid-pregnancy vitamin D levels and postpartum depression. Eur J Obstet Gynecol Reprod Biol 2014;179:110-6.
64. Maddock J1, Berry DJ, Geoffroy MC, Power C, Hyppönen E. Vitamin D and common mental disorders in mid-life: cross-sectional and prospective findings. Clin Nutr 2013;32:758-64.
65. Darwish H, Zeinoun P, Ghusn H, Khoury B, Tamim H, Khoury SJ. Serum 25-hydroxyvitamin D predicts cognitive performance in adults. Neuropsychiatr Dis Treat 2015;11:2217-23.
66. Jorde R, Sneve M, Figenschau Y, Svartberg J, Waterloo K. Effects of vitamin D supplementation on symptoms of depression in overweight and obese subjects: Randomized double-blind trial. J Intern Med 2008;264:599-609.
67. Kjærgaard M, Waterloo K, Wang CE, Almås B, Figenschau Y, Hutchinson MS, et al. Effect of vitamin D supplement on depression scores in people with low levels of serum 25-hydroxyvitamin D: nested case-control study and randomized clinical trial. Br J Psychiatry 2012;201:360-8.
68. Stokes CS, Grünhage F, Baus C, Volmer DA, Wagenpfeil S, Riemenschneider M, et al. Vitamin D supplementation reduces depressive symptoms in patients with chronic liver disease. Clin Nutr 2015;15:178-8.
69. Shaffer JA, Edmondson D, Wasson LT, Falzon L, Homma K, Ezeokoli N, et al. Vitamin D supplementation for depressive symptoms: a systematic review and meta-analysis of randomized controlled trials. Psychosom Med 2014;76:190-6.
70. Li G, Mbuagbaw L, Samaan Z, Falavigna M, Zhang S, Adachi JD, et al., Efficacy of vitamin D supplementation in depression in adults: a systematic review. J Clin Endocrinol Metab 2014;99:757-67.
71. Gowda U, Mutowo MP, Smith BJ, Wluka AE, Renzaho AM. Vitamin D supplementation to reduce depression in adults: a meta-analysis of randomized controlled trials. Nutrition 2015;31:421-9.
72. Krishnan AV, Feldman D. Activation of protein kinase-C inhibits vitamin D receptor gene expression. Mol Endocrinol 1991;5:605–12.
73. Krishnan AV, Feldman D. Cyclic adenosine 3´,5´-monophosphate up-regulates 1,25-dihydroxyvitamin D3 receptor gene expression and enhances hormone action. Mol Endocrinol 1992;6:198–206.
74. Garcion E, Wion-Barbot N, Montero-Menei CN, Berger F, Wion D. New clues about vitamin D functions in the nervous system. Trends Endocrinol Metab 2002;13:100–5.
75. Eyles DW, Smith S, Kinobe R, Hewison M, McGrath JJ. Distribution of the vitamin D receptor and 1alpha-hydroxylase in human brain. J Chem Neuroanat 2005;29:21–30.
76. Obradovic D, Gronemeyer H, Lutz B, Rein T. Cross-talk of Vitamin D and glucocorticoids in hippocampal cells. J Neurochem 2006;96:500–9.
77. Puchacz E, Stumpf W, Stachowiak EK, Stachowiak MK. Vitamin D increases expression of the tyrosine hydroxylase gene in adrenal medullary cells. Mol Brain Res 1996;36:193–6.
78. Cass WA, Smith MP, Peters LE. Calcitriol protects against the dopamine and serotonin-depleting effects of neurotoxic doses of methamphetamine. Ann N Y Acad Sci 2006;1074:261–71.
79. Patrick RP, Ames BN. Vitamin D hormone regulates serotonin synthesis. Part 1: relevance for autism. FASEB J 2014;28:2398-413.
80. Gloth FM, Alam W, Hollis B. Vitamin D vs. broad spectrum phototherapy in the treatment of seasonal effective disorder. J Nutr Health Aging 1999;3:5-7.
81. Smith RS. The macrophage theory of depression. Med Hypotheses 1991;35:298-306.
82. Maes M, Smith R, Scharpe S. The monocyte-T-lymphocyte hypothesis of major depression. Psychoneuroendocrinology 1995;20:111-6.
83. Baeke F, Takiishi T, Korf H, Gysemans C, Mathieu C. Vitamin D: modulator of the immune system. Curr Opin Pharmacol 2010;10:482‐96.
84. Zhang Y, Leung DY, Richers BN, Liu Y, Remigio LK, Riches DW. Vitamin D inhibits monocyte/macrophage pro-inflammatory cytokine production by targeting MAPK phosphatase‐1. J Immunol 2012;188:2127‐35.
85. Borges MC, Martini LA, Rogero MM. Current perspectives on vitamin D, immune system, and chronic diseases. Nutrition 2011;27:399‐40.
Statistics
378 Views | 1863 Downloads
How to Cite
Zam, W. “VITAMIN D DEFICIENCY AND DEPRESSIVE DISORDERS: REVIEW STUDY OF PROBABLE RELATIONSHIP”. International Journal of Pharmacy and Pharmaceutical Sciences, Vol. 8, no. 1, Dec. 2015, pp. 16-22, https://innovareacademics.in/journals/index.php/ijpps/article/view/8989.
Section
Review Article(s)